Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced today that the first patient has been successfully dosed in a phase I clinical trial of anti-CD47 monoclonal...
Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has dosed the first patient with COTI-2 in combination...
Eisai Inc. announced today the presentation of four abstracts at the 2019 Gastrointestinal Cancers Symposium (#GI19), taking place in San Francisco from January 17-19, 2019. The presentations feature the latest data from post-hoc analyses of the pivotal phase 3...
CEO Tom Equels sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. Equels says the company will begin clinical trials at the Roswell Park Comprehensive Cancer Center to start an oncology clinical study combining its dsRNA TLR3...
Translational Research In Oncology (TRIO), in collaboration with Novartis and under the direction of Dennis Slamon, MD, PhD, TRIO Chairman/Executive Director and Director of Clinical Translational Research at the University of California, Los Angeles Jonsson...
Email
Text